CLINICAL_TRIALS
trial_result
· 2018-09-24
Clinical Trial Update: A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease [Phase 2]
Summary
Phase 2a study evaluating rilapladib (SB-659032) in Alzheimer's disease has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GlaxoSmithKline | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2018-09-24